表紙
市場調查報告書

被套細胞淋巴瘤 (MCL) :市場預測與分析

NHL: Mantle Cell Lymphoma Disease Coverage Forecast and Market Analysis to 2034

出版商 Datamonitor Healthcare 商品編碼 633175
出版日期 內容資訊 英文 196 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
被套細胞淋巴瘤 (MCL) :市場預測與分析 NHL: Mantle Cell Lymphoma Disease Coverage Forecast and Market Analysis to 2034
出版日期: 2018年04月11日內容資訊: 英文 196 Pages
簡介

本報告提供B細胞非何杰金氏淋巴瘤的稀有型,被套細胞淋巴瘤 (MCL) 治療藥市場相關調查分析,市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等系統性資訊。

預測:被套細胞淋巴瘤 (MCL)

  • 概要
  • 摘要整理
  • 市場概要、趨勢
  • 市場定義、手法
  • IMBRUVICA (IBRUTINIB)
  • REVLIMID (LENALIDOMIDE)
  • RITUXAN (RITUXIMAB)
  • TORISEL (TEMSIROLIMUS)
  • VELCADE (BORTEZOMIB)
  • 一次調查手法

治療:被套細胞淋巴瘤 (MCL)

  • 概要
  • 摘要整理
  • 一次調查手法
  • 疾病定義、診斷
  • 患者區分
  • 各國治療樹
  • 目前治療選擇
  • 處方趨勢:局部階段 (I/II)
  • 處方趨勢:巨大階段 (II/III/IV)

流行病學:被套細胞淋巴瘤 (MCL)

  • 摘要整理
  • 產品概要
  • 產品簡介:IMBRUVICA
  • 產品簡介:REVLIMID
  • 產品簡介:RITUXAN
  • 產品簡介:TORISEL
  • 產品簡介:TREANDA
  • 產品簡介:VELCADE

開發平台:被套細胞淋巴瘤 (MCL)

  • 概要
  • 摘要整理
  • 臨床開發平台概要
  • 產品簡介 (後期階段) :DARZALEX
  • 產品簡介 (後期階段) :GAZYVA
  • 產品簡介 (後期階段) :KTE-C19
  • 產品簡介 (後期階段) :KYPROLIS
目錄
Product Code: DMKC 13367

Mantle cell lymphoma (MCL) is a rare form of B-cell non-Hodgkin's lymphoma (NHL), accounting for 3-6% of new NHL cases. The term MCL derives from the growth pattern of the lymphoma, with tumor cells originating in the mantle zone of the lymph node. The clinical behavior of MCL is usually aggressive, and the clinical presentation frequently includes extranodal involvement of the bone marrow and gut. The disease often initially responds to treatment, but disease relapse inevitably occurs within 1-2 years. The prognosis of patients with MCL is the poorest among B-cell lymphoma patients, with median overall survival of 5-7 years.

Recent events and opinion:

  • Costly therapies will drive the growth of the mantle cell lymphoma market during 2016-25, despite multiple generic/biosimilar entries.
  • Imbruvica has achieved the highest response rates among the new targeted approaches in refractory or early relapse cases, leading to its usage in previously treated patients.
  • Incident cases of the three major subtypes of NHL will increase by at least a quarter over the forecast period.
  • Rituxan-based therapies remain the standard of care for the treatment of mantle cell lymphoma.
  • CD antigens are the main targets in the pipeline for mantle cell lymphoma.

Table of Contents

(Forecast, Treatment and Epidemiology Datapacks included)

FORECAST: MANTLE CELL LYMPHOMA (Published on 15 April 2016)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • MARKET OVERVIEW AND TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • IMBRUVICA (IBRUTINIB)
  • REVLIMID (LENALIDOMIDE)
  • RITUXAN (RITUXIMAB)
  • TORISEL (TEMSIROLIMUS)
  • VELCADE (BORTEZOMIB)
  • PRIMARY RESEARCH METHODOLOGY

TREATMENT: MANTLE CELL LYMPHOMA (Published on 14 April 2016)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • COUNTRY TREATMENT TREES
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS: LOCALIZED STAGE (I/II)
  • PRESCRIBING TRENDS: BULKY STAGE (II/III/IV)

EPIDEMIOLOGY: MANTLE CELL LYMPHOMA (Published on 11 April 2018)

  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: IMBRUVICA
  • PRODUCT PROFILE: REVLIMID
  • PRODUCT PROFILE: RITUXAN
  • PRODUCT PROFILE: TORISEL
  • PRODUCT PROFILE: TREANDA
  • PRODUCT PROFILE: VELCADE

PIPELINE: MANTLE CELL LYMPHOMA (Published on 29 February 2016)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • CLINICAL PIPELINE OVERVIEW
  • PRODUCT PROFILE (LATE STAGE): DARZALEX
  • PRODUCT PROFILE (LATE STAGE): GAZYVA
  • PRODUCT PROFILE (LATE STAGE): KTE-C19
  • PRODUCT PROFILE (LATE STAGE): KYPROLIS

LIST OF FIGURES

  • Figure 1: Mantle cell lymphoma market value across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 2: Mantle cell lymphoma market value in the US, Japan, and five major EU markets, by drug status, 2016-25
  • Figure 3: Mantle cell lymphoma drug sales in the US, Japan, and five major EU markets, by drug, 2016-25
  • Figure 4: Patient-based forecast methodology for mantle cell lymphoma
  • Figure 5: Price sources and calculations, by country
  • Figure 6: Imbruvica sales for mantle cell lymphoma across the US and five major EU markets, by country, 2016-25
  • Figure 7: Revlimid sales for mantle cell lymphoma across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 8: Rituxan sales for mantle cell lymphoma across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 9: Torisel sales for mantle cell lymphoma across the five major EU markets, by country, 2016-25
  • Figure 10: Velcade sales for mantle cell lymphoma across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 11: Proportion of mantle cell lymphoma patients at localized or advanced stage of disease at diagnosis, by country, 2016
  • Figure 12: Proportion of localized stage mantle cell lymphoma patients receiving each treatment type, by country, 2016
  • Figure 13: Proportion of localized stage mantle cell lymphoma patients receiving each line of anti-cancer therapy, by country, 2016
  • Figure 14: Proportion of localized stage mantle cell lymphoma patients receiving each type of first-line/induction therapy, by country, 2016
  • Figure 15: Proportion of localized stage mantle cell lymphoma patients receiving each aggressive first-line/induction therapy, by country, 2016
  • Figure 16: Proportion of localized stage mantle cell lymphoma patients receiving each less aggressive first-line/induction therapy, by country, 2016
  • Figure 17: Proportion of localized stage mantle cell lymphoma patients receiving each first-line maintenance therapy, by country, 2016
  • Figure 18: Proportion of mantle cell lymphoma patients (irrespective of stage) receiving each second-line therapy, by country, 2016
  • Figure 19: Proportion of mantle cell lymphoma patients (irrespective of stage) receiving each second-line maintenance therapy, by country, 2016
  • Figure 20: Proportion of mantle cell lymphoma patients (irrespective of stage) receiving third-line therapy, by country, 2016
  • Figure 21: Proportion of mantle cell lymphoma patients (irrespective of stage) receiving each third-line maintenance therapy, by country, 2016
  • Figure 22: Proportion of bulky stage mantle cell lymphoma patients receiving each treatment type, by country, 2016
  • Figure 23: Proportion of bulky stage mantle cell lymphoma patients receiving each line of anti-cancer therapy, by country, 2016
  • Figure 24: Proportion of bulky stage mantle cell lymphoma patients receiving each type of first-line/induction therapy, by country, 2016
  • Figure 25: Proportion of bulky stage mantle cell lymphoma patients receiving aggressive first-line/induction therapy, by country, 2016
  • Figure 26: Proportion of bulky stage mantle cell lymphoma patients receiving less aggressive first-line/induction therapy, by country, 2016
  • Figure 27: Proportion of bulky stage mantle cell lymphoma patients receiving first-line maintenance therapy, by country, 2016
  • Figure 28: Trends in incident cases of NHL in the US, Japan, and five major EU markets, 2017-37
  • Figure 29: Trends in incident cases of DLBCL in the US, Japan, and five major EU markets, 2017-37
  • Figure 30: Trends in incident cases of FL in the US, Japan, and five major EU markets, 2017-37
  • Figure 31: Trends in incident cases of MCL in the US, Japan, and five major EU markets, 2017-37
  • Figure 32: Imbruvica for mantle cell lymphoma - SWOT analysis
  • Figure 33: Datamonitor Healthcare's drug assessment summary of Imbruvica in mantle cell lymphoma
  • Figure 34: Datamonitor Healthcare's drug assessment summary of Imbruvica in mantle cell lymphoma
  • Figure 35: Revlimid for mantle cell lymphoma - SWOT analysis
  • Figure 36: Datamonitor Healthcare's drug assessment summary of Revlimid in mantle cell lymphoma
  • Figure 37: Datamonitor Healthcare's drug assessment summary of Revlimid in mantle cell lymphoma
  • Figure 38: Rituxan for mantle cell lymphoma - SWOT analysis
  • Figure 39: Datamonitor Healthcare's drug assessment summary of Rituxan in mantle cell lymphoma
  • Figure 40: Datamonitor Healthcare's drug assessment summary of Rituxan in mantle cell lymphoma
  • Figure 41: Torisel for mantle cell lymphoma - SWOT analysis
  • Figure 42: Datamonitor Healthcare's drug assessment summary of Torisel in mantle cell lymphoma
  • Figure 43: Datamonitor Healthcare's drug assessment summary of Torisel in mantle cell lymphoma
  • Figure 44: Treanda for mantle cell lymphoma - SWOT analysis
  • Figure 45: Datamonitor Healthcare's drug assessment summary of Treanda in mantle cell lymphoma
  • Figure 46: Datamonitor Healthcare's drug assessment summary of Treanda in mantle cell lymphoma
  • Figure 47: Velcade for mantle cell lymphoma - SWOT analysis
  • Figure 48: Datamonitor Healthcare's drug assessment summary of Velcade in mantle cell lymphoma
  • Figure 49: Datamonitor Healthcare's drug assessment summary of Velcade in mantle cell lymphoma
  • Figure 50: Darzalex for mantle cell lymphoma - SWOT analysis
  • Figure 51: Gazyva for mantle cell lymphoma - SWOT analysis
  • Figure 52: KTE-C19 for mantle cell lymphoma - SWOT analysis
  • Figure 53: Kyprolis for mantle cell lymphoma - SWOT analysis

LIST OF TABLES

  • Table 1: Mantle cell lymphoma market value across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 2: Mantle cell lymphoma market value in the US, Japan, and five major EU markets, by drug status ($m), 2016-25
  • Table 3: Mantle cell lymphoma drug sales in the US, Japan, and five major EU markets, by drug, 2016-25
  • Table 4: Revlimid and Velcade sales ($m), 2016
  • Table 5: Summary of drug classes, molecules, and brands included in Datamonitor Healthcare's mantle cell lymphoma patient-based forecast
  • Table 6: Exchange rates used for calculating prices
  • Table 7: Patent expiry dates for key marketed brands in mantle cell lymphoma, by region
  • Table 8: Expected label expansion and approval in mantle cell lymphoma, 2016-25
  • Table 9: Imbruvica sales for mantle cell lymphoma across the US and five major EU markets, by country ($m), 2016-25
  • Table 10: Imbruvica patient numbers for mantle cell lymphoma across the US, Japan, and five major EU markets, by country, 2016-25
  • Table 11: Revlimid sales for mantle cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 12: Revlimid patient numbers for mantle cell lymphoma across the US, Japan, and five major EU markets, by country, 2016-25
  • Table 13: Rituxan sales for mantle cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 14: Rituxan patient numbers for mantle cell lymphoma across the US, Japan, and five major EU markets, by country, 2016-25
  • Table 15: Torisel sales for mantle cell lymphoma across the five major EU markets, by country ($m), 2016-25
  • Table 16: Torisel patient numbers for mantle cell lymphoma across the five major EU markets, by country, 2016-25
  • Table 17: Velcade sales for mantle cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 18: Velcade patient numbers for mantle cell lymphoma across the US, Japan, and five major EU markets, by country, 2016-25
  • Table 19: Hematologists and hemato-oncologists surveyed for the mantle cell lymphoma primary research study, 2016
  • Table 20: Hematologists and hemato-oncologists surveyed for the mantle cell lymphoma primary research study, 2016
  • Table 21: Simplified Mantle Cell Lymphoma International Prognostic Index
  • Table 22: Ann Arbor classification
  • Table 23: Targeted drugs for the treatment of mantle cell lymphoma
  • Table 24: Main cytotoxic therapies for the treatment of mantle cell lymphoma
  • Table 25: Cancer registry databases used as a source of NHL, DLBCL, FL, and MCL incidence data, by country
  • Table 26: Ann Arbor classification system
  • Table 27: Incident cases of NHL in the US, Japan, and five major EU markets, 2017-37
  • Table 28: Incident cases of DLBCL in the US, Japan, and five major EU markets, 2017-37
  • Table 29: Incident cases of FL in the US, Japan, and five major EU markets, 2017-37
  • Table 30: Incident cases of MCL in the US, Japan, and five major EU markets, 2017-37
  • Table 31: Key marketed drugs for mantle cell lymphoma
  • Table 32: Imbruvica drug profile
  • Table 33: Imbruvica pivotal trial data in mantle cell lymphoma
  • Table 34: Imbruvica late-phase trial data in mantle cell lymphoma
  • Table 35: Imbruvica ongoing late-phase clinical trials in mantle cell lymphoma
  • Table 36: Revlimid drug profile
  • Table 37: Revlimid pivotal trial data in mantle cell lymphoma
  • Table 38: Revlimid other trial data in mantle cell lymphoma
  • Table 39: Revlimid ongoing clinical trials in mantle cell lymphoma
  • Table 40: Rituxan drug profile
  • Table 41: Rituxan pivotal trial data in B-cell non-Hodgkin's lymphoma
  • Table 42: Rituxan clinical studies in mantle cell lymphoma
  • Table 43: Torisel drug profile
  • Table 44: Torisel pivotal trial data in mantle cell lymphoma
  • Table 45: Treanda drug profile
  • Table 46: Treanda pivotal trial data in mantle cell lymphoma
  • Table 47: Velcade drug profile
  • Table 48: Velcade pivotal trial data in mantle cell lymphoma
  • Table 49: Phase I/II pipeline products in development for mantle cell lymphoma
  • Table 50: Darzalex drug profile
  • Table 51: Darzalex Phase II trial in mantle cell lymphoma
  • Table 52: Gazyva drug profile
  • Table 53: Gazyva Phase I/II data in mantle cell lymphoma
  • Table 54: Gazyva Phase Ib/II trial in mantle cell lymphoma
  • Table 55: KTE-C19 drug profile
  • Table 56: KTE-C19 Phase I/II trials in mantle cell lymphoma
  • Table 57: Kyprolis drug profile
  • Table 58: Kyprolis Phase I/II trials in mantle cell lymphoma
Back to Top